GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence

Apr 3, 2026Future oncology (London, England)

How GLP-1 receptor drugs and immune checkpoint inhibitors may interact: a review of their mechanisms and clinical effects

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Real-world data indicate improved overall survival and fewer immune-related adverse events in patients with cancer receiving glucagon-like peptide-1 receptor agonists (GLP-1RAs) alongside immune checkpoint inhibitors (ICIs).

Obesity may enhance the effectiveness of immune checkpoint inhibitors despite its association with increased cancer risk.
Immunosuppressive mechanisms, such as regulatory T-cells and myeloid-derived suppressor cells, could limit long-term anti-tumor responses.
GLP-1RAs may serve as metabolic-immunologic adjuvants, potentially reprogramming the tumor microenvironment in obese patients undergoing ICI therapy.
Activation of specific signaling pathways by GLP-1R may suppress inflammation and improve T-cell function.
Concerns about the safety of GLP-1RAs, including risks of pancreatitis and diabetes, are not fully characterized.

AI simplified

Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immunosuppressive mechanisms, including regulatory T-cells, myeloid-derived suppressor cells, and pro-inflammatory macrophages, can limit durable anti-tumor responses. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond metabolic comorbidity management, functioning as metabolic-immunologic adjuvants capable of reprogramming the tumor microenvironment in obese patients receiving ICIs. A literature search was conducted in PubMed/MEDLINE through December 2025 using MeSH headings related to glucagon-like peptide-1 receptor agonists and immune checkpoint inhibitors. Mechanistically, GLP-1R signaling activates cAMP-PKA-AMPK pathways that suppress NF-κB-driven inflammation and promote macrophage repolarization, improving CD8 T-cell metabolic fitness, enhancing central memory formation, and reducing lipid-induced T-cell exhaustion. Real-world observational data across renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and neuroendocrine neoplasms suggest improved overall survival, fewer immune-related adverse events, and lower cardiometabolic complications with concurrent GLP-1RA and ICI therapy. Pharmacovigilance concerns regarding pancreatitis, ICI-induced diabetes, and immune-related toxicities remain incompletely characterized. This review critically appraises mechanistic insights, real-world evidence, and safety considerations, proposing a translational-clinical research agenda to prospectively validate GLP-1RAs as rational adjuncts to checkpoint blockade.

Full Text

Full text is available at the source.

View full text ↗

GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief